Add-on Anifrolumab for Residual Mucocutaneous and Systemic Manifestations During Cyclophosphamide Therapy in Severe Neuropsychiatric Lupus: A Case Report

Clicks: 13
ID: 330517
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #52 of 59 articles by views in Modern Rheumatology Case Reports

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
A 29-year-old woman presented with fever, malar rash, and alopecia. Laboratory evaluation demonstrated a high-titre antinuclear antibody of 1:5120, hypocomplementaemia, and positivity for anti-double-stranded DNA and anti-Smith antibodies, leading to a diagnosis of systemic lupus erythematosus. During the clinical course, she developed progressive peripheral neuropathy with inability to walk. Intravenous methylprednisolone pulse therapy and intravenous immunoglobulin were administered, but neurological improvement was limited, and intravenous cyclophosphamide therapy was initiated. Subsequently, she developed central nervous system manifestations of neuropsychiatric systemic lupus erythematosus and received an additional course of intravenous methylprednisolone. Central nervous system manifestations gradually improved during ongoing intravenous cyclophosphamide therapy; however, fever, rash, and alopecia persisted at the time of transfer to our hospital. Because fever persisted despite antibiotic therapy and mucocutaneous manifestations and hypocomplementaemia progressively worsened, residual systemic lupus erythematosus activity was considered clinically relevant. Anifrolumab was initiated on hospital day 28, coinciding with completion of antibiotic therapy. Fever resolved the following day, while the mucocutaneous manifestations and hypocomplementaemia subsequently showed gradual and sustained improvement. No serious infectious or other adverse events were observed after anifrolumab initiation during ongoing intravenous cyclophosphamide therapy. Reports describing add-on anifrolumab during ongoing intravenous cyclophosphamide therapy for severe systemic lupus erythematosus are extremely limited. This case highlights the potential role of anifrolumab as an adjunctive therapy for persistent systemic and mucocutaneous manifestations suggestive of interferon-associated disease activity during ongoing cyclophosphamide-based intensive immunosuppressive treatment.
Reference Key
openalex_W7214766888 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mariko Hoshino, Toshihiko Shiga, Yumi Morimoto, Jinhai Li, Yuji Nozaki, Koji Kinoshita, Shinya Rai
Are you one of these authors? Claim your profile
Journal Modern Rheumatology Case Reports
Year 2026
DOI
10.1093/mrcr/rxag092
URL
https://doi.org/10.1093/mrcr/rxag092
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.